Therapeutic activity and biodistribution of a nano-sized
polymer-dexamethasone conjugate intended for the targeted
treatment of rheumatoid arthritis

J 2024

Therapeutic activity and biodistribution of a nano-sized polymer-dexamethasone conjugate intended for the targeted treatment of rheumatoid arthritis

RUBANOVÁ, Daniela, Svitlana SKOROPLYAS, Alena LIBANSKA, Eva RANDAROVA, Josef BRYJA et. al.

Základní údaje

Originální název

Therapeutic activity and biodistribution of a nano-sized polymer-dexamethasone conjugate intended for the targeted treatment of rheumatoid arthritis

Autoři

RUBANOVÁ, Daniela (203 Česká republika, domácí), Svitlana SKOROPLYAS (804 Ukrajina, domácí), Alena LIBANSKA, Eva RANDAROVA, Josef BRYJA (203 Česká republika, domácí), Michaela CHORVÁTOVÁ (703 Slovensko, domácí), Tomas ETRYCH a Lukas KUBALA

Vydání

Nanomedicine: Nanotechnology, Biology and Medicine, Elsevier, 2024, 1549-9634

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30226 Rheumatology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.400 v roce 2022

Organizační jednotka

Přírodovědecká fakulta

DOI

http://dx.doi.org/10.1016/j.nano.2023.102716

UT WoS

001110181400001

Klíčová slova anglicky

Dexamethasone; Rheumatoid arthritis; HPMA; RANKL; Biodistribution

Štítky

rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 31. 1. 2024 12:38, Mgr. Marie Šípková, DiS.

Anotace

V originále

Rheumatoid arthritis is a chronic inflammatory autoimmune disease caused by alteration of the immune system. Current therapies have several limitations and the use of nanomedicines represents a promising strategy to overcome them. By employing a mouse model of adjuvant induced arthritis, we aimed to evaluate the bio-distribution and therapeutic effects of glucocorticoid dexamethasone conjugated to a nanocarrier based on biocompatible N-(2-hydroxypropyl) methacrylamide copolymers. We observed an increased accumulation of dexamethasone polymer nanomedicines in the arthritic mouse paw using non-invasive fluorescent in vivo im-aging and confirmed it by the analysis of tissue homogenates. The dexamethasone conjugate exhibited a dose-dependent healing effect on arthritis and an improved therapeutic outcome compared to free dexamethasone. Particularly, significant reduction of accumulation of RA mediator RANKL was observed. Overall, our data suggest that the conjugation of dexamethasone to a polymer nanocarrier by means of stimuli-sensitive spacer is suitable strategy for improving rheumatoid arthritis therapy.

Citovat

RUBANOVÁ, Daniela, Svitlana SKOROPLYAS, Alena LIBANSKA, Eva RANDAROVA, Josef BRYJA, Michaela CHORVÁTOVÁ, Tomas ETRYCH a Lukas KUBALA. Therapeutic activity and biodistribution of a nano-sized polymer-dexamethasone conjugate intended for the targeted treatment of rheumatoid arthritis. Nanomedicine: Nanotechnology, Biology and Medicine. Elsevier, 2024, roč. 55, January, s. 1-10. ISSN 1549-9634. Dostupné z: https://dx.doi.org/10.1016/j.nano.2023.102716.

@article{2368110,
   author = {Rubanová, Daniela and Skoroplyas, Svitlana and Libanska, Alena and Randarova, Eva and Bryja, Josef and Chorvátová, Michaela and Etrych, Tomas and Kubala, Lukas},
   article_number = {January},
   doi = {http://dx.doi.org/10.1016/j.nano.2023.102716},
   keywords = {Dexamethasone; Rheumatoid arthritis; HPMA; RANKL; Biodistribution},
   language = {eng},
   issn = {1549-9634},
   journal = {Nanomedicine: Nanotechnology, Biology and Medicine},
   title = {Therapeutic activity and biodistribution of a nano-sized polymer-dexamethasone conjugate intended for the targeted treatment of rheumatoid arthritis},
   url = {https://www.sciencedirect.com/science/article/pii/S1549963423000679},
   volume = {55},
   year = {2024}
}

TY  - JOUR
ID  - 2368110
AU  - Rubanová, Daniela - Skoroplyas, Svitlana - Libanska, Alena - Randarova, Eva - Bryja, Josef - Chorvátová, Michaela - Etrych, Tomas - Kubala, Lukas
PY  - 2024
TI  - Therapeutic activity and biodistribution of a nano-sized polymer-dexamethasone conjugate intended for the targeted treatment of rheumatoid arthritis
JF  - Nanomedicine: Nanotechnology, Biology and Medicine
VL  - 55
IS  - January
SP  - 1-10
EP  - 1-10
PB  - Elsevier
SN  - 15499634
KW  - Dexamethasone
KW  - Rheumatoid arthritis
KW  - HPMA
KW  - RANKL
KW  - Biodistribution
UR  - https://www.sciencedirect.com/science/article/pii/S1549963423000679
N2  - Rheumatoid arthritis is a chronic inflammatory autoimmune disease caused by alteration of the immune system. Current therapies have several limitations and the use of nanomedicines represents a promising strategy to overcome them. By employing a mouse model of adjuvant induced arthritis, we aimed to evaluate the bio-distribution and therapeutic effects of glucocorticoid dexamethasone conjugated to a nanocarrier based on biocompatible N-(2-hydroxypropyl) methacrylamide copolymers. We observed an increased accumulation of dexamethasone polymer nanomedicines in the arthritic mouse paw using non-invasive fluorescent in vivo im-aging and confirmed it by the analysis of tissue homogenates. The dexamethasone conjugate exhibited a dose-dependent healing effect on arthritis and an improved therapeutic outcome compared to free dexamethasone. Particularly, significant reduction of accumulation of RA mediator RANKL was observed. Overall, our data suggest that the conjugation of dexamethasone to a polymer nanocarrier by means of stimuli-sensitive spacer is suitable strategy for improving rheumatoid arthritis therapy.
ER  -

RUBANOVÁ, Daniela, Svitlana SKOROPLYAS, Alena LIBANSKA, Eva RANDAROVA, Josef BRYJA, Michaela CHORVÁTOVÁ, Tomas ETRYCH a Lukas KUBALA. Therapeutic activity and biodistribution of a nano-sized polymer-dexamethasone conjugate intended for the targeted treatment of rheumatoid arthritis. \textit{Nanomedicine: Nanotechnology, Biology and Medicine}. Elsevier, 2024, roč.~55, January, s.~1-10. ISSN~1549-9634. Dostupné z: https://dx.doi.org/10.1016/j.nano.2023.102716.

Podrobný výpis o publikaci